Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
October 3, 2023
Compact, single-use, on-body injector designed to enhance the patient experience of administering EMPAVELI® (pegcetacoplan) WALTHAM, Mass., – Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S.